Our Team
We take teamwork seriously and use a holistic approach to anticipate future issues.
J. Suzanne Lindsey, PhD, President, Founder and Chief Scientific Officer, discovered our platform, and lead target Mig7. She designed and directed the generation, validation, and utilization of Mig7 polyclonal and monoclonal antibodies as well as other targeting reagents. She was previously a founder and VP of a VC-funded biotech in Seattle. In addition to 30 years of business and science experience, Dr. Lindsey passed the patent bar exam and prosecuted molecular and therapeutic patent applications. Dr. Lindsey earned a Ph.D. in molecular microbiology and immunology from Oregon Health and Science University, a B.S. in Applied Science magna cum laude from Pacific University, and was a postdoctoral fellow in endometrial molecular biology at the Oregon Regional Primate Research Center.
David A. Cheresh, PhD, serves as Scientific Advisor and was also scientific founder of TargeGen Inc which was acquired by Sanofi. He is currently Distinguished Professor, Department of Pathology; Professor and Associate Director for Translational Research, Moores Cancer Center,; Vice Chair for Research, Associate Director, Institute of Engineering in Medicine; all UCSD, La Jolla, CA. Dr. Cheresh’s experience includes discovery and co-development of monoclonal antibodies, preclinical research, antibody humanization, and FDA approval of antibody therapies.
Christopher Scull, PhD serves as regulatory advisor. As a consultant for Biologics and FDA Investigational New Drugs (IND) applications, Dr. Scull’s expertise includes product development strategy, design and management of pharmacology and toxicology studies, writing and reviewing FDA submissions, and achieving GLP compliance. He served as Global Director of Discovery Sciences at Innovimmune Biotherapeutics, where he managed development of a portfolio of pre-IND drug candidates. Dr. Scull was responsible for preclinical development planning and management of nonclinical studies. He also served in multiple roles at Memorial Sloan Kettering Cancer Center. As a member of the Investigational Products team, he co-authored and reviewed IND applications and assisted investigators with FDA compliance during the design and conduct of pharmacology and toxicology studies.
Randy Clawson serves as financial advisor. He earned his B.A. in Finance from West Texas A&M University. He was a retail Account Executive for Merrill Lynch with experience in stocks, bonds, options, commodities, insurance products and annuities. Mr. Clawson has 30 years of financial training and experience in accounting, inventory control and cash flow analyses. Randy is also experienced in budget preparation, securing bank loans and alternative financing.